3SBio (TRSBF) Institutional Ownership : 17.81% (As of Jul. 02, 2025)

View and export this data going back to 2018. Start your Free Trial

What is 3SBio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 3SBio's institutional ownership is 17.81%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 3SBio's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 3SBio's Float Percentage Of Total Shares Outstanding is 0.00%.

3SBio Institutional Ownership Historical Data

The historical data trend for 3SBio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Institutional Ownership Chart

3SBio Historical Data

The historical data trend for 3SBio can be seen below:

	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31
Institutional Ownership	20.71	20.95	21.17	21.38	21.43	21.38	21.55	20.91	20.73	20.86

3SBio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

3SBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

01530:Hong Kong 83B:Germany

Address

No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027

Website

https://www.3sbio.com

3SBio Inc is a biotechnology company. As a pioneer in the Chinese biotechnology industry, the Group has extensive expertise in researching, developing, manufacturing, and marketing biopharmaceuticals. The core products of the Group include several biopharmaceutical drugs, TPIAO recombinant human erythropoietin rhEPO products EPIAO and SEPO, Yisaipu, Cipterbin, and a small molecule drug, Mandi. Except for minoxidil, an over-the-counter drug, the others are all older-generation biologics.

3SBio Headlines

From GuruFocus

Wall Street Can't Ignore This: China's Biotech Stocks Are Exploding--One Is Up 283%

By Khac Phu Nguyen • 06-17-2025